FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.

被引：16
|
作者：
Krauss, Aviva C.
Mulkey, Flora
Shen, Yuan-Li
Rosenberg, Amy
Miller, Barry
Carioti, Theresa
Scott, Kimberly
Gormley, Nicole
Theoret, Marc Robert
Sridhara, Rajeshwari
Farrell, Ann T.
Pazdur, Richard
机构：
[1] US FDA, Silver Spring, MD USA
[2] NCI, NIH, Bethesda, MD 20892 USA
[3] US FDA, Bethesda, MD 20014 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8008
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Germline determinants of immune related adverse events (irAEs) in melanoma immunotherapy response
    Kirchhoff, T.
    Ferguson, R.
    Simpson, D.
    Kazlow, E.
    Martinez, C.
    Vogelsang, M.
    Wilson, M.
    Pavlick, A. C.
    Weber, J. S.
    Osman, I.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials
    Zhou, Yixin
    Yu, Hui
    Chen, Chen
    Li, Anlin
    Zhang, Xuanye
    Qiu, Huijuan
    Du, Wei
    Fu, Sha
    Zhang, Li
    Hong, Shaodong
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [3] Incidence of immune-related adverse events with pembrolizumab in advanced melanoma and correlation with treatment response: A single institution review of irAEs.
    Myrdal, Caitlyn N.
    Mehta, Paras
    Smith, Eric
    Briones, Kimberly
    Albright, Jason
    Curiel-Lewandrowski, Clara
    McBride, Ali
    Sundararajan, Srinath
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
    Batista-Duharte, Alexander
    Alino, Salvador F. F.
    [J]. FRONTIERS IN ALLERGY, 2023, 4
  • [5] Reporting of immune-related adverse events (irAEs) in US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
    Tapiavala, Shaili
    Shenouda, Mina A.
    Patel, Vaibhav G.
    Davis, Andrew A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
    Liu, Yi-He
    Zang, Xin-Yuan
    Wang, Jin-Cheng
    Huang, Shan-Shan
    Xu, Jiang
    Zhang, Peng
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 120
  • [7] The chronology of immune-related adverse events (irAEs)-mechanistic implications
    Mazahreh, Farah
    Safar, Haya
    Mazahreh, Liyan
    Safar, A. Mazin
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [8] Immune-related adverse events (IrAEs) as a predictor of response to immunotherapy in patients with lung cancer
    Sanchez Becerra, M. V.
    Martinez-Cabanes, R.
    Gonzalez-Lopez, A.
    Zhan-Zhou, E.
    Sotelo, V.
    Esteban, M.
    Robles, T.
    Camara, J. C.
    Cardena, A.
    Hernando, S.
    Hurtado, A.
    Moreno, D.
    Olier, C.
    Mielgo Rubio, X.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S808 - S809
  • [9] Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis
    Wang, QuanQiu
    Xu, Rong
    [J]. JAMIA OPEN, 2019, 2 (01) : 173 - 178
  • [10] DISTRIBUTION OF IMMUNE-RELATED ADVERSE EVENTS (IRAES) IN SOLID MALIGNANCIES
    Kaakour, Dalia
    Slaught, Matthew
    Azizi, Armon
    Kroening, Gianna
    Valerin, Jennifer
    Mar, Nataliya
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1293 - A1293
12345